Rocket Pharmaceuticals (RCKT) Projected to Post Earnings on Monday

Rocket Pharmaceuticals (NASDAQ:RCKT) is expected to be posting its quarterly earnings results before the market opens on Monday, February 24th. Analysts expect Rocket Pharmaceuticals to post earnings of ($0.68) per share and revenue of $0.03 million for the quarter.

Rocket Pharmaceuticals Price Performance

Shares of NASDAQ RCKT opened at $10.47 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The stock has a fifty day moving average price of $11.34 and a 200 day moving average price of $15.33. Rocket Pharmaceuticals has a 1-year low of $9.33 and a 1-year high of $31.47. The company has a market cap of $954.45 million, a PE ratio of -3.81 and a beta of 0.98.

Wall Street Analysts Forecast Growth

RCKT has been the subject of a number of recent analyst reports. Leerink Partners reduced their target price on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday, November 19th. Wedbush initiated coverage on Rocket Pharmaceuticals in a report on Monday, December 30th. They issued an “outperform” rating and a $32.00 target price for the company. Chardan Capital reissued a “buy” rating and issued a $62.00 target price on shares of Rocket Pharmaceuticals in a report on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Rocket Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $47.27.

Insider Buying and Selling at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah sold 11,091 shares of Rocket Pharmaceuticals stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $13.05, for a total value of $144,737.55. Following the transaction, the chief executive officer now directly owns 707,328 shares of the company’s stock, valued at $9,230,630.40. The trade was a 1.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 14,386 shares of company stock worth $185,345 in the last 90 days. 28.50% of the stock is owned by company insiders.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.